Review



rat brain protein extract  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology rat brain protein extract
    Rat Brain Protein Extract, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 45144 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat brain protein extract/product/Santa Cruz Biotechnology
    Average 96 stars, based on 45144 article reviews
    rat brain protein extract - by Bioz Stars, 2026-04
    96/100 stars

    Images



    Similar Products

    rat brain protein extract  (Santa Cruz Biotechnology)
    96
    Santa Cruz Biotechnology rat brain protein extract
    Rat Brain Protein Extract, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat brain protein extract/product/Santa Cruz Biotechnology
    Average 96 stars, based on 1 article reviews
    rat brain protein extract - by Bioz Stars, 2026-04
    96/100 stars
    		  Buy from Supplier
    cytosolic extracts  (Cusabio)
    94
    Cusabio cytosolic extracts
    Cytosolic Extracts, supplied by Cusabio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cytosolic extracts/product/Cusabio
    Average 94 stars, based on 1 article reviews
    cytosolic extracts - by Bioz Stars, 2026-04
    94/100 stars
    		  Buy from Supplier
    atm  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology atm
    <t>WRN‐mediated</t> NF‐κB activation requires CHK1 and PARP1. (a) U2‐OS Cells were treated with CPT (50 nM) for indicated time periods, and activation of DDR proteins was assessed by Western blotting. (b) NEMO‐knockdown (NEMO‐KD) U2‐OS cells were generated by lentivirus mediated shRNA expression system. Expression of NEMO protein in NEMO‐WT (control shRNA) and NEMO‐KD cells was assessed by Western blotting. (c) NEMO‐WT and NEMO‐KD cells were treated with CPT (50 nM) for indicated time periods, and NF‐κB activation was assessed in terms of IκBα degradation by Western blotting. (d) <t>ATM‐knockdown</t> (ATM‐KD) U2‐OS cells were generated by lentivirus mediated shRNA expression system. Expression of ATM protein in ATM‐WT (control shRNA) and ATM‐KD cells was assessed by Western blotting. (e) ATM‐WT and ATM‐KD cells were treated with CPT (50 nM) for indicated time periods, and NF‐κB activation was assessed in term of IκBα degradation by Western blotting. (f) WRN‐WT cells expressing NF‐κB driven luciferase reporter were treated with CPT (50 nM) in the absence or presence of CHK1i or PARP1i for indicated time periods and NF‐κB activation was assessed in terms of fold increase in luciferase activity, which is normalized by renilla expression. All the values indicated are mean ± SD ( n = 3 for a, c, e) or mean ± SEM ( n = 4 for f). ** p < 0.01 with respect to vehicle treatment at respective time points
    Atm, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/atm/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    atm - by Bioz Stars, 2026-04
    93/100 stars
    		  Buy from Supplier
    sc 23921  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology sc 23921
    <t>WRN‐mediated</t> NF‐κB activation requires CHK1 and PARP1. (a) U2‐OS Cells were treated with CPT (50 nM) for indicated time periods, and activation of DDR proteins was assessed by Western blotting. (b) NEMO‐knockdown (NEMO‐KD) U2‐OS cells were generated by lentivirus mediated shRNA expression system. Expression of NEMO protein in NEMO‐WT (control shRNA) and NEMO‐KD cells was assessed by Western blotting. (c) NEMO‐WT and NEMO‐KD cells were treated with CPT (50 nM) for indicated time periods, and NF‐κB activation was assessed in terms of IκBα degradation by Western blotting. (d) <t>ATM‐knockdown</t> (ATM‐KD) U2‐OS cells were generated by lentivirus mediated shRNA expression system. Expression of ATM protein in ATM‐WT (control shRNA) and ATM‐KD cells was assessed by Western blotting. (e) ATM‐WT and ATM‐KD cells were treated with CPT (50 nM) for indicated time periods, and NF‐κB activation was assessed in term of IκBα degradation by Western blotting. (f) WRN‐WT cells expressing NF‐κB driven luciferase reporter were treated with CPT (50 nM) in the absence or presence of CHK1i or PARP1i for indicated time periods and NF‐κB activation was assessed in terms of fold increase in luciferase activity, which is normalized by renilla expression. All the values indicated are mean ± SD ( n = 3 for a, c, e) or mean ± SEM ( n = 4 for f). ** p < 0.01 with respect to vehicle treatment at respective time points
    Sc 23921, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sc 23921/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    sc 23921 - by Bioz Stars, 2026-04
    93/100 stars
    		  Buy from Supplier
    anti atm 2c1  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology anti atm 2c1
    <t>WRN‐mediated</t> NF‐κB activation requires CHK1 and PARP1. (a) U2‐OS Cells were treated with CPT (50 nM) for indicated time periods, and activation of DDR proteins was assessed by Western blotting. (b) NEMO‐knockdown (NEMO‐KD) U2‐OS cells were generated by lentivirus mediated shRNA expression system. Expression of NEMO protein in NEMO‐WT (control shRNA) and NEMO‐KD cells was assessed by Western blotting. (c) NEMO‐WT and NEMO‐KD cells were treated with CPT (50 nM) for indicated time periods, and NF‐κB activation was assessed in terms of IκBα degradation by Western blotting. (d) <t>ATM‐knockdown</t> (ATM‐KD) U2‐OS cells were generated by lentivirus mediated shRNA expression system. Expression of ATM protein in ATM‐WT (control shRNA) and ATM‐KD cells was assessed by Western blotting. (e) ATM‐WT and ATM‐KD cells were treated with CPT (50 nM) for indicated time periods, and NF‐κB activation was assessed in term of IκBα degradation by Western blotting. (f) WRN‐WT cells expressing NF‐κB driven luciferase reporter were treated with CPT (50 nM) in the absence or presence of CHK1i or PARP1i for indicated time periods and NF‐κB activation was assessed in terms of fold increase in luciferase activity, which is normalized by renilla expression. All the values indicated are mean ± SD ( n = 3 for a, c, e) or mean ± SEM ( n = 4 for f). ** p < 0.01 with respect to vehicle treatment at respective time points
    Anti Atm 2c1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti atm 2c1/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    anti atm 2c1 - by Bioz Stars, 2026-04
    93/100 stars
    		  Buy from Supplier
    mouse anti atm  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology mouse anti atm
    <t>WRN‐mediated</t> NF‐κB activation requires CHK1 and PARP1. (a) U2‐OS Cells were treated with CPT (50 nM) for indicated time periods, and activation of DDR proteins was assessed by Western blotting. (b) NEMO‐knockdown (NEMO‐KD) U2‐OS cells were generated by lentivirus mediated shRNA expression system. Expression of NEMO protein in NEMO‐WT (control shRNA) and NEMO‐KD cells was assessed by Western blotting. (c) NEMO‐WT and NEMO‐KD cells were treated with CPT (50 nM) for indicated time periods, and NF‐κB activation was assessed in terms of IκBα degradation by Western blotting. (d) <t>ATM‐knockdown</t> (ATM‐KD) U2‐OS cells were generated by lentivirus mediated shRNA expression system. Expression of ATM protein in ATM‐WT (control shRNA) and ATM‐KD cells was assessed by Western blotting. (e) ATM‐WT and ATM‐KD cells were treated with CPT (50 nM) for indicated time periods, and NF‐κB activation was assessed in term of IκBα degradation by Western blotting. (f) WRN‐WT cells expressing NF‐κB driven luciferase reporter were treated with CPT (50 nM) in the absence or presence of CHK1i or PARP1i for indicated time periods and NF‐κB activation was assessed in terms of fold increase in luciferase activity, which is normalized by renilla expression. All the values indicated are mean ± SD ( n = 3 for a, c, e) or mean ± SEM ( n = 4 for f). ** p < 0.01 with respect to vehicle treatment at respective time points
    Mouse Anti Atm, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti atm/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    mouse anti atm - by Bioz Stars, 2026-04
    93/100 stars
    		  Buy from Supplier
    rat brain sections  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology rat brain sections
    <t>WRN‐mediated</t> NF‐κB activation requires CHK1 and PARP1. (a) U2‐OS Cells were treated with CPT (50 nM) for indicated time periods, and activation of DDR proteins was assessed by Western blotting. (b) NEMO‐knockdown (NEMO‐KD) U2‐OS cells were generated by lentivirus mediated shRNA expression system. Expression of NEMO protein in NEMO‐WT (control shRNA) and NEMO‐KD cells was assessed by Western blotting. (c) NEMO‐WT and NEMO‐KD cells were treated with CPT (50 nM) for indicated time periods, and NF‐κB activation was assessed in terms of IκBα degradation by Western blotting. (d) <t>ATM‐knockdown</t> (ATM‐KD) U2‐OS cells were generated by lentivirus mediated shRNA expression system. Expression of ATM protein in ATM‐WT (control shRNA) and ATM‐KD cells was assessed by Western blotting. (e) ATM‐WT and ATM‐KD cells were treated with CPT (50 nM) for indicated time periods, and NF‐κB activation was assessed in term of IκBα degradation by Western blotting. (f) WRN‐WT cells expressing NF‐κB driven luciferase reporter were treated with CPT (50 nM) in the absence or presence of CHK1i or PARP1i for indicated time periods and NF‐κB activation was assessed in terms of fold increase in luciferase activity, which is normalized by renilla expression. All the values indicated are mean ± SD ( n = 3 for a, c, e) or mean ± SEM ( n = 4 for f). ** p < 0.01 with respect to vehicle treatment at respective time points
    Rat Brain Sections, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat brain sections/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    rat brain sections - by Bioz Stars, 2026-04
    93/100 stars
    		  Buy from Supplier
    antibodies against atm  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology antibodies against atm
    <t>WRN‐mediated</t> NF‐κB activation requires CHK1 and PARP1. (a) U2‐OS Cells were treated with CPT (50 nM) for indicated time periods, and activation of DDR proteins was assessed by Western blotting. (b) NEMO‐knockdown (NEMO‐KD) U2‐OS cells were generated by lentivirus mediated shRNA expression system. Expression of NEMO protein in NEMO‐WT (control shRNA) and NEMO‐KD cells was assessed by Western blotting. (c) NEMO‐WT and NEMO‐KD cells were treated with CPT (50 nM) for indicated time periods, and NF‐κB activation was assessed in terms of IκBα degradation by Western blotting. (d) <t>ATM‐knockdown</t> (ATM‐KD) U2‐OS cells were generated by lentivirus mediated shRNA expression system. Expression of ATM protein in ATM‐WT (control shRNA) and ATM‐KD cells was assessed by Western blotting. (e) ATM‐WT and ATM‐KD cells were treated with CPT (50 nM) for indicated time periods, and NF‐κB activation was assessed in term of IκBα degradation by Western blotting. (f) WRN‐WT cells expressing NF‐κB driven luciferase reporter were treated with CPT (50 nM) in the absence or presence of CHK1i or PARP1i for indicated time periods and NF‐κB activation was assessed in terms of fold increase in luciferase activity, which is normalized by renilla expression. All the values indicated are mean ± SD ( n = 3 for a, c, e) or mean ± SEM ( n = 4 for f). ** p < 0.01 with respect to vehicle treatment at respective time points
    Antibodies Against Atm, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibodies against atm/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    antibodies against atm - by Bioz Stars, 2026-04
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    WRN‐mediated NF‐κB activation requires CHK1 and PARP1. (a) U2‐OS Cells were treated with CPT (50 nM) for indicated time periods, and activation of DDR proteins was assessed by Western blotting. (b) NEMO‐knockdown (NEMO‐KD) U2‐OS cells were generated by lentivirus mediated shRNA expression system. Expression of NEMO protein in NEMO‐WT (control shRNA) and NEMO‐KD cells was assessed by Western blotting. (c) NEMO‐WT and NEMO‐KD cells were treated with CPT (50 nM) for indicated time periods, and NF‐κB activation was assessed in terms of IκBα degradation by Western blotting. (d) ATM‐knockdown (ATM‐KD) U2‐OS cells were generated by lentivirus mediated shRNA expression system. Expression of ATM protein in ATM‐WT (control shRNA) and ATM‐KD cells was assessed by Western blotting. (e) ATM‐WT and ATM‐KD cells were treated with CPT (50 nM) for indicated time periods, and NF‐κB activation was assessed in term of IκBα degradation by Western blotting. (f) WRN‐WT cells expressing NF‐κB driven luciferase reporter were treated with CPT (50 nM) in the absence or presence of CHK1i or PARP1i for indicated time periods and NF‐κB activation was assessed in terms of fold increase in luciferase activity, which is normalized by renilla expression. All the values indicated are mean ± SD ( n = 3 for a, c, e) or mean ± SEM ( n = 4 for f). ** p < 0.01 with respect to vehicle treatment at respective time points

    Journal: Aging Cell

    Article Title: Non‐enzymatic function of WRN RECQL helicase regulates removal of topoisomerase‐I‐DNA covalent complexes and triggers NF‐κB signaling in cancer

    doi: 10.1111/acel.13625

    Figure Lengend Snippet: WRN‐mediated NF‐κB activation requires CHK1 and PARP1. (a) U2‐OS Cells were treated with CPT (50 nM) for indicated time periods, and activation of DDR proteins was assessed by Western blotting. (b) NEMO‐knockdown (NEMO‐KD) U2‐OS cells were generated by lentivirus mediated shRNA expression system. Expression of NEMO protein in NEMO‐WT (control shRNA) and NEMO‐KD cells was assessed by Western blotting. (c) NEMO‐WT and NEMO‐KD cells were treated with CPT (50 nM) for indicated time periods, and NF‐κB activation was assessed in terms of IκBα degradation by Western blotting. (d) ATM‐knockdown (ATM‐KD) U2‐OS cells were generated by lentivirus mediated shRNA expression system. Expression of ATM protein in ATM‐WT (control shRNA) and ATM‐KD cells was assessed by Western blotting. (e) ATM‐WT and ATM‐KD cells were treated with CPT (50 nM) for indicated time periods, and NF‐κB activation was assessed in term of IκBα degradation by Western blotting. (f) WRN‐WT cells expressing NF‐κB driven luciferase reporter were treated with CPT (50 nM) in the absence or presence of CHK1i or PARP1i for indicated time periods and NF‐κB activation was assessed in terms of fold increase in luciferase activity, which is normalized by renilla expression. All the values indicated are mean ± SD ( n = 3 for a, c, e) or mean ± SEM ( n = 4 for f). ** p < 0.01 with respect to vehicle treatment at respective time points

    Article Snippet: Antibodies against p65, WRN (#SC5629), ATM (#SC23921), CHK1 (#SC8404), Lamin B (#SC6216), and CRISPR‐Cas9 double nickase plasmid (control and WRN) were from Santa Cruz biotechnology (Santa Cruz, CA).

    Techniques: Activation Assay, Western Blot, Knockdown, Generated, shRNA, Expressing, Control, Luciferase, Activity Assay